In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bard EP Deal Latest In Boston Scientific’s M&A Revival, Bolsters CRM Business

Executive Summary

Boston Scientific’s recent acquisition of Bard Electrophysiology marks the tenth notable acquisition that it has made since 2010. Four of those deals come in cardiac rhythm management, including EP, which is among the fastest-growing device sectors and one that company executives see as a major contributor to future growth.


Related Content

Device/Diagnostics Quarterly Deal Statistics, Q2 2013
SJM’s Endosense Deal Highlights Growing Importance Of Contact Force Technology In AF Ablation
New Paradigms Brewing In Atrial Fibrillation Ablation
New Product Briefs: Abbott Glucose Monitor, Boston Sci EP Mapping System Gain 510(k)s
PROTECT AF Results Show Long-Term Efficacy Of Watchman LAA Closure Device
Boston Scientific Says PREVAIL Results Affirm Safety of Watchman LAA Anti-Stroke Device
Device Companies Follow New Map To Atrial Fibrillation
Cameron Health: Is This The Cure For An Ailing ICD Market?


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts